lifestyle.capitolhilltimes.com

Author: Cognition Therapeutics, Inc.

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

April 7, 2026
Cognition Therapeutics CEO Issues Letter to Shareholders

March 31, 2026
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

March 26, 2026
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

March 23, 2026
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

March 17, 2026
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

March 2, 2026
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

February 11, 2026
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

January 27, 2026